Jutta Schreiner

Title: Jutta Schreiner: Innovator in Hematology

Introduction

Jutta Schreiner is a prominent inventor based in Vienna, Austria. She has made significant contributions to the field of hematology, particularly in the treatment of von Willebrand disease (VWD). With a total of six patents to her name, her work focuses on innovative methods for testing and measuring the effectiveness of treatments for this condition.

Latest Patents

One of her latest patents involves methods for testing the effectiveness of a von Willebrand factor used in treating VWD. This invention relates to measuring VWF cleavage fragments in a blood sample from a subject before and after treatment. An increase in VWF cleavage fragments after treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) is cleaving the VWF. Conversely, a decrease or absence of VWF cleavage fragments suggests that endogenous ADAMTS13 is not cleaving the VWF. Another significant patent focuses on methods of measuring ADAMTS13 activity, specifically the ability of ADAMTS13 to cleave VWF in vivo. This invention also explores various animal models that demonstrate ADAMTS13 activity similar to that of humans.

Career Highlights

Throughout her career, Jutta has worked with notable companies such as Baxalta GmbH and Baxter International Inc. Her expertise in the field has led to advancements in the understanding and treatment of blood disorders.

Collaborations

Jutta has collaborated with esteemed colleagues, including Katalin Varadi and Hanspeter Rottensteiner. These partnerships have further enriched her research and contributions to the field.

Conclusion

Jutta Schreiner's innovative work in hematology has paved the way for improved treatments for von Willebrand disease. Her patents reflect her dedication to advancing medical science and enhancing patient care.